Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$167.94
0.0%
$169.61
$111.09
$183.00
$10.27B0.38482,678 shs22,188 shs
Qiagen N.V. stock logo
QGEN
Qiagen
$48.59
+1.1%
$45.95
$37.63
$49.30
$10.79B0.681.22 million shs262,157 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$39.70
-3.5%
$33.76
$6.76
$46.98
$3.78B0.331.32 million shs209,724 shs
Viatris Inc. stock logo
VTRS
Viatris
$9.05
+1.7%
$8.88
$6.85
$13.55
$10.59B0.8910.94 million shs623,319 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.11%-3.92%-5.02%+5.59%+24.27%
Qiagen N.V. stock logo
QGEN
Qiagen
-0.61%-0.40%+2.86%+13.52%+18.96%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+0.98%+6.56%+20.80%+29.96%+372.10%
Viatris Inc. stock logo
VTRS
Viatris
+0.23%-2.63%+0.34%+15.73%-24.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.5998 of 5 stars
4.53.00.00.02.81.70.6
Qiagen N.V. stock logo
QGEN
Qiagen
3.7694 of 5 stars
1.24.01.74.52.61.71.3
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.1393 of 5 stars
1.61.00.04.42.63.30.6
Viatris Inc. stock logo
VTRS
Viatris
2.6516 of 5 stars
1.94.02.50.01.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$223.0732.83% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.30
Hold$49.401.68% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.13
Buy$42.677.47% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.80
Reduce$10.4014.94% Upside

Current Analyst Ratings Breakdown

Latest SRRK, ASND, VTRS, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
7/11/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$213.00 ➝ $243.00
7/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$250.00
6/26/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $53.00
6/24/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$55.00
6/18/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/6/2025
Viatris Inc. stock logo
VTRS
Viatris
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$10.00
6/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$196.00 ➝ $201.00
6/3/2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M26.10N/AN/A($1.88) per share-89.33
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.46$3.22 per share15.09$16.05 per share3.03
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$33.19M113.57N/AN/A$3.94 per share10.08
Viatris Inc. stock logo
VTRS
Viatris
$14.74B0.72$5.20 per share1.74$15.61 per share0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A699.75N/A-93.22%N/A-33.29%9/2/2025 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$0.40121.7019.752.464.68%14.61%8.80%8/5/2025 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
-$634.20M-$3.17N/A3.52N/A-26.45%16.20%7.01%8/7/2025 (Estimated)

Latest SRRK, ASND, VTRS, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.68N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.56N/AN/AN/A$3.46 billionN/A
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60N/AN/AN/A$523.97 millionN/A
5/14/2025Q1 2025
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.49$0.50+$0.01-$2.55$3.30 billion$3.25 billion
5/7/2025Q1 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.51%N/A62.50%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
Viatris Inc. stock logo
VTRS
Viatris
$0.485.31%N/AN/A N/A

Latest SRRK, ASND, VTRS, and QGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%7/2/20257/3/20257/10/2025
5/5/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.55%5/23/20255/23/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.71
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.16
10.25
10.25
Viatris Inc. stock logo
VTRS
Viatris
1.02
1.68
0.97

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
13.30%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.15 million36.69 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
14094.95 million82.32 millionOptionable
Viatris Inc. stock logo
VTRS
Viatris
32,0001.17 billion1.17 billionOptionable

Recent News About These Companies

Viatris Phase III MR-139 trial in blepharitis misses goal
Viatris: A Contrarian Bet With Virtually No Downside
Viatris Certified as a Great Place to Work® in Canada
13 Best Low Priced Pharma Stocks to Buy Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$167.94 -0.08 (-0.05%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Qiagen stock logo

Qiagen NYSE:QGEN

$48.56 +0.50 (+1.04%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$39.79 -1.33 (-3.22%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viatris stock logo

Viatris NASDAQ:VTRS

$9.00 +0.10 (+1.16%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.